We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacokinetic profile of Optivate<sup>®</sup> (high-purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease.
- Authors
Shaikh‐Zaidi, R.; Lubetsky, A.; Inbal, A.; Dash, C.
- Abstract
The aricle discusses the pharmacokinetic profile of Optivate for the treatment of von Willebrand disease (VWD), the commonest congenital bleeding disorder. It cites the clinical study funded by the biotechnology company Bio Products Laboratory Ltd. which compares the pharmacokinetic (PK) of Optivate and Haemate P in VWD patients. It states that the composition of Optivate has been shown to be comparable to other von Willebrand factor (VWF)/factor III concentrates, and was well tolerated.
- Subjects
PHARMACOKINETICS; VON Willebrand disease treatment; VON Willebrand factor; BLOOD coagulation factors; HEMORRHAGIC diseases; BLOOD coagulation disorders; THERAPEUTICS
- Publication
Haemophilia, 2016, Vol 22, Issue 1, pe64
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.12843